Archives: Market Insights

Stem cell therapies are moving from experimental to clinical applications across orthopedics, cardiac, and neurological conditions, creating investment opportunities across the value chain. Read more

Compression therapy devices, contrast therapy systems, and recovery technology represent a fast-growing premium wellness category with attractive unit economics. Read more

Contract development and manufacturing organizations are capturing an increasing share of pharmaceutical production as drug companies focus on R&D and outsource manufacturing to specialized partners. Read more

The first 100 days after an acquisition close are the most critical. A proven integration playbook that captures synergies while preserving business momentum, employee morale, and customer relationships. Read more

Customer success management has evolved from a support function to a revenue growth driver in B2B technology companies, with direct impact on churn, expansion revenue, and customer lifetime value. Read more

The most transformative investments back companies that fundamentally innovate their business models — creating new value for customers that displaces incumbents and defines new categories. Read more

Net Promoter Score is the single most predictive metric for long-term business success. How IKON Group uses NPS measurement across our portfolio to identify growth opportunities and retention risks. Read more

Real options analysis gives investors a framework for valuing flexibility — the ability to delay, expand, contract, or abandon investments — often overlooked in traditional DCF analysis. Read more

Healthcare brands face unique digital marketing challenges balancing FDA and FTC regulatory compliance with effective customer acquisition and brand building strategies. Read more

The journey from peptide research discovery to commercial therapeutic product — an overview of the development, regulatory, and manufacturing processes relevant to IKON Group’s biotech portfolio. Read more